Medicine and Dentistry
Acute Toxicity
10%
Atrium (Heart)
6%
Bilevel Positive Airway Pressure
6%
Breast Cancer
6%
Breathing
12%
Cardiovascular System
13%
Chemoradiotherapy
50%
Computer Assisted Tomography
6%
Cone Beam Computed Tomography
8%
Conformal Radiotherapy
12%
Continuous Positive Airway Pressure
6%
Contouring
13%
Dose Calculation
11%
Dose-Volume Histogram
7%
Durvalumab
15%
Fluorodeoxyglucose F 18
7%
Head and Neck Tumor
6%
Hypoxia
6%
Image Quality
11%
Immunotherapy
13%
Intensity Modulated Radiation Therapy
23%
Lung Cancer
50%
Lung Tumor
9%
Neoplasm
28%
Non Small Cell Lung Cancer
100%
Non-Small Cell Lung Cancer
13%
Odds Ratio
8%
Overall Survival
22%
Photon Therapy
12%
Pneumonia
6%
Positron Emission Tomography
11%
Positron Emission Tomography
6%
Primary Tumor
11%
Proteus
6%
Proton Therapy
72%
Radiation Oncology
7%
Radiation Pneumonia
18%
Radiation Therapy
33%
Radiation Therapy
13%
Radiation Therapy Planning
7%
Small Cell Lung Cancer
13%
Stereotactic Body Radiation Therapy
12%
Stereotactic Radiotherapy
7%
Survival Prediction
6%
Thorax Tumor
13%
Ticilimumab
6%
Tumor Metabolism
6%
Ventricle (Heart)
6%
Volume CT
14%
Volumetric Modulated Arc Therapy
12%
Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
6%
3-month Mortality
6%
4D Dose Accumulation
18%
4D Dose Reconstruction
11%
4DCT
6%
Acute Toxicity
13%
Assessment Method
6%
Cancer Audit
7%
Cardiac Atria
6%
CD8+ T Cell Infiltration
6%
Chemoradiotherapy
28%
Concurrent Chemoradiotherapy
8%
Deep Learning
7%
Dose-surface Maps
6%
Dosimetric Parameters
8%
Dutch
7%
Early Response Monitoring
6%
Esophageal Toxicity
11%
External Validation
7%
Image Features
6%
Immune Checkpoint Inhibitors
6%
Intensity-modulated
13%
Interface Test
6%
Intrafraction
6%
Large-scale Motions
6%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
15%
Lung Cancer
20%
Multivariable
20%
National Cohort Study
13%
Netherlands
6%
Non-gated
6%
Non-responders
6%
Non-small Cell Lung Cancer (NSCLC)
17%
Non-small Cell Lung Cancer Patients
47%
Normal Tissue Complication Probability
13%
Normal Tissue Complication Probability Models
12%
Normal Tissue Complications
6%
Organs at Risk
7%
Overall Survival
13%
Proton Dose
6%
Radiation Dose
6%
Radiation Pneumonitis
8%
Radiotherapy
15%
Radiotherapy Boost
6%
Reader Study
6%
Stage I Lung Cancer
13%
Stage I-IIIA
6%
Stage III Non-small Cell Lung Cancer
13%
Stereotactic Body Radiotherapy
10%
Stereotactic Radiotherapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Toxicity
10%
Brain Metastasis
6%
Cancer Staging
6%
Chemoradiation Therapy
67%
Chemotherapy
7%
Chemotherapy Regimens
6%
Cisplatin
9%
Durvalumab
13%
Heart Left Ventricle Failure
6%
Hodgkin Disease
6%
Immunotherapy
8%
Lung Cancer
48%
Lung Toxicity
5%
Malignant Neoplasm
21%
Neoplasm
10%
Non Small Cell Lung Cancer
93%
Overall Survival
22%
Pneumonia
6%
Primary Tumor
13%
Radiation Pneumonia
21%
Survival Prediction
6%
Thorax Tumor
6%
Tolerability
6%
Tremelimumab
6%
